GAD Treatment Genetic Testing for Psychiatric Medication for GAD By Arlin Cuncic Arlin Cuncic Arlin Cuncic, MA, is the author of "Therapy in Focus: What to Expect from CBT for Social Anxiety Disorder" and "7 Weeks to Reduce Anxiety." Learn about our editorial process Updated on November 19, 2020 Medically reviewed Verywell Mind articles are reviewed by board-certified physicians and mental healthcare professionals. Medical Reviewers confirm the content is thorough and accurate, reflecting the latest evidence-based research. Content is reviewed before publication and upon substantial updates. Learn more. by Steven Gans, MD Medically reviewed by Steven Gans, MD Steven Gans, MD is board-certified in psychiatry and is an active supervisor, teacher, and mentor at Massachusetts General Hospital. Learn about our Medical Review Board Print BraunS / Getty Images Genetic testing for psychiatric medication for generalized anxiety disorder (GAD) is based on an area of research called "pharmacogenetics." In its simplest terms, this area of research involves studying how medications interact with inherited genes. In other words, people differ in their responses to different medications—both in terms of pharmacokinetics, how a drug is metabolized, and pharmacodynamics, how a drug works at its particular target in the brain—because of their unique genetic profile the same drug might be perfectly safe for one person, but harmful to another. If you've ever been prescribed psychiatric medication, you might know that it's not an exact science. Often it involves a process of trial and error, in which your doctor tries out a series of medications until the best one and best dose is identified. The objective of this new process of matching medication to your genetic profile aims to eliminate that period of trial and error. Benefits It's easy to imagine what the benefits could be of knowing what medications will work best for you before you ever take them. Dr. Jim Kennedy of the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada described the potential benefits of genetic testing for psychiatric medication during a press conference about this new line of research: "Using the genetic blueprint of our bodies... we can measure in the lab... and create a very easy-to-understand test that is provided to your doctor to help show what medications are very good for a particular patient, and what medications will not work well, and may have some nasty side effects." In essence, genetic testing of this sort may ultimately allow your doctor to personalize your anxiety treatment. The hope is that there will be less trial and error when prescribing medication for your symptoms. This may also result in an economic benefit, in that when the most helpful medication is prescribed, money isn't spent on other less helpful medications. CAMH, in cooperation with a genetic testing firm, is conducting ongoing research on this topic, led by Dr. Kennedy. Although currently the available pharmacogenetic testing for psychotropic medication is of unclear value in many treatment decision, the hope is that in the near future, every patient will have a personalized medication experience. This will also help to improve patient safety, as those at risk for adverse effects may be identified before being prescribed certain medications. Research Findings As reported at the World Congress of Psychiatric Genetics in Orlando, FL in October 2017, Tiwari and colleagues showed that genetic testing for psychiatric medication significantly improved the effects of treatment for generalized anxiety disorder, and reduced the use of benzodiazepines, a short-term medication for treating anxiety. Their findings were based on data from the Individualized Medicine: Pharmacogenetic Assessment and Clinical Treatment (IMPACT) study and the MEDCO dataset. Steps in Genetic Testing for Psychiatric Medication In the IMPACT Study, which is ongoing through CAMH, genetic testing is conducted through a saliva sample, similar to what you would submit to companies such as 23 and ME. The test may predict how you will respond to various psychiatric medications and any side effects you might experience. This is determined based on your genetic profile and how your body is expected to metabolize different medications. Understanding Pharmacogenetics Pharmacogenetics involves looking for variations in genes that may affect pharmacokinetics or pharmacodynamics. There is individual variability in the genes that affect how a drug is metabolized and how it works in the body. Some people might break down medications slowly, while other people might process them quickly. Side effects can be the result of a medication remaining in a high concentration in the body because a person doesn't metabolize them as quickly. Barriers to Implementation Quite simply, genetic testing for medication can be expensive if you do not have insurance coverage. In addition, the availability of tests will be an issue until this type of testing becomes more mainstream. A Word From Verywell It is important to note that in spite of research efforts like the ones outlined here, there is still not the kind of evidence (multiple randomized double-blinded studies) to support the consistent utilization of these genetic tests in everyday clinical psychiatric practice. If you want to raise this topic with your doctor, ask how the available genetic tests might be potentially helpful in your particular treatment. Becoming an informed patient will help you to feel more in control of your prescriptions. 5 Sources Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Singh DB. The Impact of Pharmacogenomics in Personalized Medicine. Adv Biochem Eng Biotechnol. 2020;171:369-394. doi:10.1007/10_2019_110 Stern S, Linker S, Vadodaria KC, Marchetto MC, Gage FH. Prediction of response to drug therapy in psychiatric disorders. Open Biol. 2018;8(5). doi:10.1098/rsob.180031 Smoller JW. Psychiatric genetics and the future of personalized treatment. Depress Anxiety. 2014;31(11):893-8. doi:10.1002/da.22322 Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test. Ont Health Technol Assess Ser. 2017;17(4):1-39. Aradhya S, Nussbaum RL. Genetics in mainstream medicine: Finally within grasp to influence healthcare globally. Mol Genet Genomic Med. 2018. Additional Reading Centre for Addiction and Mental Health. CAMH and Assurex Health Launch Joint Venture to Advance Personalized Medicine in Canada Healio Psychiatric Annals. GeneSight Improves Treatment Response, Decreases Benzodiazepine Use in Anxiety. Centre for Addiction and Mental Health. The Impact Study. Tiwari AK, et al. Combinational pharmacogenomic testing improves generalized anxiety disorder treatment response and decreases benzodiazepine use. Presented at: World Congress of Psychiatric Genetics; Oct. 13-17, 2017; Orlando, Florida. By Arlin Cuncic Arlin Cuncic, MA, is the author of "Therapy in Focus: What to Expect from CBT for Social Anxiety Disorder" and "7 Weeks to Reduce Anxiety." See Our Editorial Process Meet Our Review Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit Speak to a Therapist for GAD Advertiser Disclosure × The offers that appear in this table are from partnerships from which Verywell Mind receives compensation.